L&E Sees Increase in Zofran Lawsuits, More Expected

Langdon & Emison is handling a growing number of lawsuits alleging the anti-nausea drug Zofran – used off-label to treat morning sickness – caused birth defects.  

Zofran is a prescription drug approved by the U.S. Food and Drug Administration in 1991 to treat patients who experience nausea and vomiting from surgery or chemotherapy and radiation treatments; however, increasingly doctors have prescribed Zofran “off-label” to treat severe morning sickness during the first trimester of pregnancy.

Recent studies have linked a number of birth defects to Zofran, including but not limited to heart defects, including heart murmur or hole in the heart, as well as cleft clip or cleft palate.

Zofran is not approved for use during pregnancy, but by 2013, more than 1 million pregnant women per year were using Zofran.

In the last decade, Zofran has been used more commonly to treat symptoms of severe morning sickness such as uncontrollable vomiting requiring hospitalization, severe dehydration and weight loss, nutritional deficiencies and other symptoms that pose serious risks to the mother and fetus.

Hundreds of lawsuits have been filed against drug giant GlaxoSmithKline, the manufacturer of Zofran. More lawsuits are expected as attorneys review more birth defect claims.

Free Case Evaluation

If you or someone you know has a child born with a defect that may have been caused by Zofran use during pregnancy, contact Langdon & Emison for a free case evaluation at 1-800-397-4910 or click here.